BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Voors AA, Shah SJ, Bax JJ, Butler J, Gheorghiade M, Hernandez AF, Kitzman DW, McMurray JJV, Wirtz AB, Lanius V, van der Laan M, Solomon SD. Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. Eur J Heart Fail 2018;20:1601-10. [PMID: 30225882 DOI: 10.1002/ejhf.1295] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Del Buono MG, Iannaccone G, Scacciavillani R, Carbone S, Camilli M, Niccoli G, Borlaug BA, Lavie CJ, Arena R, Crea F, Abbate A. Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence. Progress in Cardiovascular Diseases 2020;63:570-84. [DOI: 10.1016/j.pcad.2020.04.011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
2 IJzerman AP, Jacobson KA, Müller CE, Cronstein BN, Cunha RA. International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update. Pharmacol Rev 2022;74:340-72. [PMID: 35302044 DOI: 10.1124/pharmrev.121.000445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
3 Campos-Martins A, Bragança B, Correia-de-Sá P, Fontes-Sousa AP. Pharmacological Tuning of Adenosine Signal Nuances Underlying Heart Failure With Preserved Ejection Fraction. Front Pharmacol 2021;12:724320. [PMID: 34489711 DOI: 10.3389/fphar.2021.724320] [Reference Citation Analysis]
4 D'Amario D, Migliaro S, Borovac JA, Restivo A, Vergallo R, Galli M, Leone AM, Montone RA, Niccoli G, Aspromonte N, Crea F. Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. Front Physiol. 2019;10:1347. [PMID: 31749710 DOI: 10.3389/fphys.2019.01347] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
5 Voors AA, Bax JJ, Hernandez AF, Wirtz AB, Pap AF, Ferreira AC, Senni M, van der Laan M, Butler J; PANTHEON Investigators. Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. Eur J Heart Fail 2019;21:1426-33. [PMID: 31523892 DOI: 10.1002/ejhf.1591] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
6 Bonaventura A, Wohlford GF, Vecchié A, Van Tassel BW, Abbate A. In-Hospital Initiation of Sacubitril/Valsartan: A New PARADIGM for Acute Decompensated Heart Failure? J Cardiovasc Pharmacol 2019;74:1-3. [PMID: 31274835 DOI: 10.1097/FJC.0000000000000685] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Shah SJ, Voors AA, McMurray JJV, Kitzman DW, Viethen T, Bomfim Wirtz A, Huang E, Pap AF, Solomon SD. Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA 2019;321:2101-12. [PMID: 31162568 DOI: 10.1001/jama.2019.6717] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 10.7] [Reference Citation Analysis]
8 Lim YMF, Molnar M, Vaartjes I, Savarese G, Eijkemans MJC, Uijl A, Vradi E, Suzart-Woischnik K, Brugts JJ, Brunner-La Rocca HP, Blanc-Guillemaud V, Couvelard F, Baudier C, Dyszynski T, Waechter S, Lund LH, Hoes AW, Tyl B, Asselbergs FW, Gerlinger C, Grobbee DE, Cronin M, Koudstaal S. Generalisability of Randomised Controlled Trials in Heart Failure with Reduced Ejection Fraction. Eur Heart J Qual Care Clin Outcomes 2021:qcab070. [PMID: 34596659 DOI: 10.1093/ehjqcco/qcab070] [Reference Citation Analysis]
9 Wintrich J, Kindermann I, Ukena C, Selejan S, Werner C, Maack C, Laufs U, Tschöpe C, Anker SD, Lam CSP, Voors AA, Böhm M. Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clin Res Cardiol 2020;109:1079-98. [PMID: 32236720 DOI: 10.1007/s00392-020-01633-w] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 14.5] [Reference Citation Analysis]
10 Bertero E, Maack C. The Partial AdeNosine A1 receptor agonist in patients with Chronic Heart failure and preserved Ejection fraction (PANACHE) trial. Cardiovascular Research 2019;115:e71-3. [DOI: 10.1093/cvr/cvz123] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
11 Jackson AO, Meng J, Tang H, Yin K. High-density lipoprotein-mediated cardioprotection in heart failure. Heart Fail Rev 2021;26:767-80. [PMID: 31984450 DOI: 10.1007/s10741-020-09916-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Metra M. November 2018 at a glance: from prediction of heart failure in asymptomatic subjects to advanced chronic heart failure. Eur J Heart Fail 2018;20:1503-4. [PMID: 30451351 DOI: 10.1002/ejhf.1014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Lin Y, Fu S, Yao Y, Li Y, Zhao Y, Luo L. Heart failure with preserved ejection fraction based on aging and comorbidities. J Transl Med 2021;19:291. [PMID: 34229717 DOI: 10.1186/s12967-021-02935-x] [Reference Citation Analysis]
14 Reiss AB, Grossfeld D, Kasselman LJ, Renna HA, Vernice NA, Drewes W, Konig J, Carsons SE, DeLeon J. Adenosine and the Cardiovascular System. Am J Cardiovasc Drugs 2019;19:449-64. [PMID: 30972618 DOI: 10.1007/s40256-019-00345-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
15 Daubert MA, Douglas PS. Primary Prevention of Heart Failure in Women. JACC Heart Fail 2019;7:181-91. [PMID: 30819373 DOI: 10.1016/j.jchf.2019.01.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
16 Sabbah HN. Targeting the Mitochondria in Heart Failure: A Translational Perspective. JACC Basic Transl Sci 2020;5:88-106. [PMID: 32043022 DOI: 10.1016/j.jacbts.2019.07.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
17 Wernly B, Zhou 周稚超 Z. More purinergic receptors deserve attention as therapeutic targets for the treatment of cardiovascular disease. Am J Physiol Heart Circ Physiol 2020;319:H723-9. [PMID: 32822211 DOI: 10.1152/ajpheart.00417.2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]